lymphoma

Mirna Therapeutics and collaborators at the University of Zurich reported last week that the company's therapeutic microRNA-34a mimic, dubbed MRX34, could inhibit tumor growth in an animal model of lymphoma, expanding the potential use of the agent to new cancer types.

Originally published April 9.
By Turna Ray

By Molika Ashford

By Adam Bonislawski
A team led by Stanford University researchers has developed a method for predicting response to cancer therapies based on cellular signaling protein dynamics and changes in tumor size.

The study confirmed expected immune system behavior and offered insights into the transition of hematopoietic cells through known stages of development. It also provided a profile of normal signaling against which data on diseased cells such as cancer cells can be compared, said one of the researchers.

In the first study, four AIDS patients with lymphoma received treatment and are doing well, with no signs of treatment-related adverse effects.